BORTEZOMIB HETERO bortezomib 3.5 mg powder for injection vial

País: Austrália

Língua: inglês

Origem: Department of Health (Therapeutic Goods Administration)

Ingredientes ativos:

bortezomib, Quantity: 3.5 mg

Disponível em:

Hetero Australia Pty Ltd

Forma farmacêutica:

Injection, powder for

Composição:

Excipient Ingredients: mannitol

Via de administração:

Intravenous Bolus, Subcutaneous

Unidades em pacote:

1 vial

Tipo de prescrição:

(S4) Prescription Only Medicine

Indicações terapêuticas:

BORTEZOMIB HETERO in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy. BORTEZOMIB HETERO as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. BORTEZOMIB HETERO is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease. BORTEZOMIB HETERO in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.

Resumo do produto:

Visual Identification: White to off-white cake or powder contained in a clear glass vial; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Status de autorização:

Registered

Data de autorização:

2021-08-05